Multipl Sklerozda Hastalık Modifiye Edici Tedaviler: İnfüzyon Tedavileri

Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Arch Neurol. 2011 Apr 11;68(4):437.

Cross A, Riley C. Treatment of Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology. 2022 Aug;28(4):1025–51.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, et al. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinflamm. 2019 Sep;6(5).

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2006 Mar 2;354(9):899–910.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2006 Mar 2;354(9):911–23.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LME, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015 Dec 25;15(1):174.

Margoni M, Rinaldi F, Riccardi A, Franciotta S, Perini P, Gallo P. No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab. J Neurol. 2020 Jan 27;267(1):100–5.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. Pediatr Neurol. 2017 May;70:56–60.

Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, et al. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis. Neurology. 2024 Apr 9;102(7).

Puthenparampil M, Gaggiola M, Ponzano M, Zanotelli G, Miscioscia A, Nosadini M, et al. High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5).

Kornbluh AB, Kahn I. Pediatric Multiple Sclerosis. Semin Pediatr Neurol. 2023 Jul;46:101054.

Sharma K, Ballham SA, Inglis KEA, Renowden S, Cottrell DA. Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion. Mult Scler Relat Disord. 2013 Oct;2(4):385–7.

Margoni M, Rinaldi F, Perini P, Gallo P. Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities. Front Neurol. 2021 May 17;12.

Suntornlohanakul R, Yeh EA. Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered? Pediatric Drugs. 2024 Dec 26;

Langer-Gould A, Sotirchos ES, Bourdette D. Rituximab for Multiple Sclerosis. Neurology. 2024 Jan 23;102(2).

Krysko KM, Graves J, Rensel M, Weinstock-Guttman B, Aaen G, Benson L, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018 Nov 6;91(19).

Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022 Jan 8;269(1):159–83.

Macaron G, Feng J, Moodley M, Rensel M. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Curr Treat Options Neurol. 2019 Oct 27;21(10):50.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan 27;5(1):22–33.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. New England Journal of Medicine. 2008 Feb 14;358(7):676–88.

Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial. Ann Neurol. 2009 Oct 8;66(4):460–71.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis. Neurology. 2016 Nov 15;87(20):2074–81.

Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016 Feb 24;263(2):322–6.

Breu M, Sandesjö F, Milos R, Svoboda J, Salzer J, Schneider L, et al. Rituximab treatment in pediatric‐onset multiple sclerosis. Eur J Neurol. 2024 May 20;31(5).

McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021 Feb 3;4(2):e2036321.

Dale RC, Brilot F, Duffy L V., Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142–50.

Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021 Jun 7;87(6):2511–20.

Syed YY. Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs. 2018 Sep 31;32(9):883–90.

Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: Beyond B-cells. Blood Rev. 2013 Sep;27(5):217–23.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2017 Jan 19;376(3):221–34.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine. 2017 Jan 19;376(3):209–20.

Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, et al. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Mar;10(2).

Malani Shukla N, Casper TC, Ness J, Wheeler Y, Chitnis T, Lotze T, et al. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatr Neurol. 2023 Aug;145:125–31.

Spirek B, Brenton JN. Safety and Efficacy of Fingolimod and Ocrelizumab in Pediatric Patients With Multiple Sclerosis. Pediatr Neurol. 2025 Mar;164:89–96.

Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, et al. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul;87:105647.

Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020 Dec;133(12):1380-1390.e2.

Syed YY. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. Drugs. 2021 Jan 24;81(1):157–68.

Alemtuzumab Product Information. www.ema.europa.eu/en/medicines/human/EPAR/lemtrada#product-info. 2024.

Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J Clin Cell Immunol. 2013 Jul 8;4(4).

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 2012 Nov;380(9856):1819–28.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012 Nov;380(9856):1829–39.

Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, et al. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023 Jan 21;16.

Jure Hunt D, Traboulsee A. Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2020 Apr 1;6(2).

Margoni M, Rinaldi F, Miante S, Franciotta S, Perini P, Gallo P. Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. 2019 Jul 16;5(3).

Puthenparampil M, Gaggiola M, Miscioscia A, Mauceri VA, De Napoli F, Zanotelli G, et al. Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis. Ther Adv Neurol Disord. 2023 Jan 6;16.

Scott LJ, Figgitt DP. Mitoxantrone. CNS Drugs. 2004;18(6):379–96.

“Mitoxantrone.” LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases. In 2020.